CRDF Earnings
Cardiff Oncology Inc
$
2.170
Earning Analysis
Welcome to our in-depth analysis of Cardiff Oncology Inc(CRDF) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Cardiff Oncology Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-11-06 | - | -0.20 | - | - | 121.43K | 120.00K | -1.18 | +0.45 | +2.23 |
| FY2025Q1 | 2025-05-08 | - | -0.19 | - | - | 89.29K | 109.00K | +22.07 | -1.09 | -6.93 |
| FY2024Q4 | 2025-02-27 | After Hours | -0.25 | -0.21 | +16.00 | 94.17K | 151.00K | +60.35 | +4.43 | -4.43 |
| FY2024Q2 | 2024-08-08 | After Hours | -0.25 | -0.26 | +4.00 | 58.75K | 163.00K | +177.45 | +11.74 | +12.21 |
| FY2024Q1 | 2024-05-02 | - | -0.25 | -0.22 | +12.00 | 55.00K | 205.00K | +272.73 | +5.91 | -24.35 |
| FY2023Q4 | 2024-02-29 | - | -0.26 | -0.21 | +19.23 | 37.50K | 156.00K | +316.00 | -2.75 | +113.74 |
| FY2023Q3 | 2023-11-02 | - | -0.29 | -0.22 | +24.14 | 37.50K | 141.00K | +276.00 | +8.57 | +3.81 |
| FY2023Q2 | 2023-08-09 | - | -0.27 | -0.25 | +7.41 | 55.60K | 108.00K | +94.24 | -12.39 | -8.26 |
| - | 2023-05-04 | - | -0.23 | -0.25 | -8.70 | - | - | - | +4.84 | -8.06 |
| - | 2023-03-02 | - | -0.25 | -0.20 | +20.00 | - | - | - | +0.58 | +18.02 |
CRDF Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Cardiff Oncology Inc reported performance for FY2025Q3, announced on 2025-11-06. The company achieved an EPS of , compared to analyst estimates of -0.20 by % . Revenue for the quarter reached 120.00K compared to expectations of 121.43K by -1.18% .
The stock price reacted with a 0.45% one-day change and a 2.23% five-day change following the earnings release. These movements reflect market reaction in Cardiff Oncology Inc growth trajectory and strategic initiatives.
CRDF Earnings Forecast
Looking ahead, Cardiff Oncology Inc(CRDF) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 80.00K and an EPS of -0.17.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Downward by -34.12% . These revisions correlate with a -11.07% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Cardiff Oncology Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between CRDF's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Downward
-34.12%
In Past 3 Month
Stock Price
Go Down
-11.07%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:427.50K
--
EPS Estimate-Annual FY 2025:-0.83
—
Stock Price2.17
CRDF Revenue and EPS Performance: A Historical Perspective
Cardiff Oncology Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-06,):
EPS: (Actual) vs.-0.20 (Estimate) (%)
Revenue: 120.00K (Actual) vs. 121.43K (Estimate) (-1.18%)
Price Reaction: 0.45%(1-Day), 2.23%(5-Day)
FY2025Q1 (2025-05-08,):
EPS: (Actual) vs.-0.19 (Estimate) (%)
Revenue: 109.00K (Actual) vs. 89.29K (Estimate) (22.07%)
Price Reaction: -1.09%(1-Day), -6.93%(5-Day)
FY2024Q4 (2025-02-27,After Hours):
EPS: -0.21 (Actual) vs.-0.25 (Estimate) (16.00%)
Revenue: 151.00K (Actual) vs. 94.17K (Estimate) (60.35%)
Price Reaction: 4.43%(1-Day), -4.43%(5-Day)
Earnings Reaction
The chart below shows how CRDF performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CRDF sees a -2.80% change in stock price 10 days leading up to the earnings, and a +17.97% change 10 days following the report. On the earnings day itself, the stock moves by +0.14%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -2.67% on the day following the earnings release and then changed by -3.56% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Call Summary
Neutral
2025-02-27
The earnings call presents a balanced picture. Financially, the company shows a solid cash position and runway, but faces risks from regulatory changes and market competition. The Q&A reveals positive clinical progress but lacks clarity on timelines, which could concern investors. The $40 million capital raise is a positive, but the absence of specific guidance and potential delays in trials offset this. Overall, the sentiment is neutral as positives are balanced by uncertainties and risks.
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Summary
Neutral
2024-08-10
The earnings call summary presents a mixed outlook. Financials show a stable cash position with a runway until Q3 2025, but high cash usage raises financial sustainability concerns. Clinical developments are promising, particularly in mCRC and ovarian cancer, yet regulatory and competitive risks loom large. The Q&A session reveals steady trial enrollment and strategic partnerships, but lacks clarity on scientific validation. Overall, the balance of positive clinical updates and financial/market risks suggests a neutral stock price movement in the near term.
People Also Watch
LWLG
Lightwave Logic Inc
4.880
USD
+1.67%
BPRN
Princeton Bancorp Inc
33.500
USD
+0.09%
SGMO
Sangamo Therapeutics Inc
0.454
USD
+1.11%
FUND
Sprott Focus Trust Inc
8.365
USD
0.00%
RCEL
AVITA Medical Inc
3.725
USD
-0.40%
FLYX
Flyexclusive Inc
3.310
USD
+3.12%
NC
NACCO Industries Inc
50.520
USD
+0.14%
ABEO
Abeona Therapeutics Inc
4.455
USD
-1.66%
PLCE
Children's Place Inc
8.790
USD
+1.15%
CRD.B
Crawford & Co
10.560
USD
-1.12%
FAQ
What were the key highlights of CRDF’s latest earnings report for FY2025Q3?
CRDF reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 120.00K against an estimate of 121.43K, resulting in a -1.18% surprise. The EPS was 0, surpassing the expected -0.2 by 0% . The stock experienced a 0.45% price change on the earnings day and a 2.23% change over the next five days, reflecting market reactions to the results.
How did CRDF’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for CRDF for 2025/Q4?
How does CRDF’s stock price correlate with earnings forecast revisions?
What should investors expect from CRDF’s next earnings report?